Uterine Sarcoma Market research report, type
(LMS, undifferentiated sarcoma), diagnosis (sampling & testing, imaging
tests), treatment (surgery, radiation therapy, hormone therapy), end users
(Hospitals, Research Organization) - global forecast till 2023
Market Scenario:
Sarcomas are the tumours of the
mesenchymal tissues like bone, muscle, connective tissue, cartilage and fat. Uterine
sarcoma is a rare type of cancer which starts in the muscle and supporting
tissues of the uterus. Exposure to the X-rays increases the risk for uterine
sarcoma. Unusual vaginal bleeding, spotting, or discharge are some of the
common symptoms for the disease. Increasing prevalence of the uterine sarcoma
and growing female geriatric population are the major drivers for the market
growth during the forecast period, 2017-2023. In 2017, according to the
American Cancer Society, 4,910 new cases of uterine sarcomas were reported in
the U.S. Moreover, according to the World Bank, the female population which
aged over 65 years rose from 316.27 billion to 347.25 billion in 2016.
Additionally, rising healthcare expenditures and
increasing awareness regarding women health is expected to boost the market
growth. However, high cost of treatment and related side effects are the
factors that can restrain the market growth. Chemotherapy is extensively
exploited for the therapeutics of the uterine sarcoma. Some of the side effects
of the chemotherapy are inclusive of hair loss, anemia, reduced fertility, and
others.
The market for global uterine sarcoma is
expected to grow at an approximate CAGR of 8.5% from 2017 to 2023.
Key players
·
Pfizer Inc.
·
Intas Pharmaceuticals Ltd.
·
FMC Corporation
·
Sun Pharmaceutical Industries Ltd.
·
Johnson & Johnson Services, Inc.
·
General Electric Company
·
Koninklijke Philips N.V.
·
Siemens Healthcare Private Limited
Segmentation
The global uterine sarcoma market is
segmented on the basis of type, diagnosis, treatment, and end user.
On the basis of the treatment, the market
is segmented into surgery, radiotherapy, chemotherapy, hormone therapy, and others.
The surgery segment is sub-segmented into bilateral salpingo-oophorectomy,
hysterectomy, and others. The chemotherapy segment is sub-segmented into
dacarbazine, docetaxel, doxorubicin, and others. The hormone therapy segment is
sub segmented into progestins, aromatase inhibitors, and others.
On the basis of the type, the market is
segmented into uterine leiomyosarcoma (LMS), endometrial stromal sarcoma (ESS),
undifferentiated sarcoma, and others.
On the basis of the diagnosis, the market
is categorised into sampling & testing, imaging tests, and others. The
sampling & testing segmented is sub-segmented into endometrial biopsy,
dilation and curettage, cystoscopy and proctoscopy, and others. The imaging
tests segment is sub segmented into transvaginal ultrasound, computed
tomography, magnetic resonance imaging, positron emission tomography scan, and
others.
On the basis of end users, the market is
segmented into hospitals & clinics, academic institutes research
organization, and others.
Regional Analysis
Asia Pacific region is also regarded to
be the fastest growing market. Increasing awareness for women health and
growing healthcare sector are the major drivers for the market growth within
the region. Moreover, the presence of the developing countries like the India
and China within the region fuels the market growth. According to the Indian
Brand Equity Foundation in 2017, the Indian healthcare sector was one of the
fastest growing industries in India and is expected to advance at a CAGR of
22.87% from 2015-2020.
America dominates the global uterine sarcoma market
owing to increasing adoption of new technologies and huge patient population.
Additionally, rising healthcare expenditure and presence of a developed
healthcare sector within the region fuels the market growth.
Europe is the second largest market for
uterine sarcoma owing to rising research and development in healthcare sector
and huge patient population. By region, Europe is divided into Western
Europe and Eastern Europe. The presence of developed economies like France,
Germany, Italy have made the Western Europe to lead the market within the
region. On the other hand, Eastern Europe is the fastest growing region in
Europe.
The Middle East & Africa has the
least share in the global uterine sarcoma market due to presence of poor
economies and stringent government policies, especially in the African region.
Majority of the market of Middle & Africa region is held by the Middle East
due to a well-developed healthcare sector and huge healthcare expenditure by
the presence of the economies like Saudi Arabia, Kuwait and Qatar within the
region.
Browse more
Life Sciences Reports @ https://www.marketresearchfuture.com/categories/life-sciences-market-report
No comments:
Post a Comment